About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Flublok or Fluzone With Advax-CpG55.2 or AF03

Clinicaltrials.gov identifier NCT03945825

Recruitment Status Completed

First Posted May 10, 2019

Last update posted March 2, 2021

Study Description

Brief summary:

This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of either the 2018/2019 seasonal Fluzone or Flublok Quadrivalent Influenza Vaccine (QIV) manufactured by Sanofi Pasteur (SP) given without adjuvant or with one of two adjuvant formulations, AF03 or Advax-CpG55.2. Eight Vaccine and Treatment Evaluation Unit (VTEU) sites will be included in the study. Study duration is approximately 18 months, and subject participation duration is 12 months. The primary objectives of this study are: 1) to assess the safety and reactogenicity of 2018/2019 Fluzone and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 2) to assess the serum hemagglutination inhibition (HAI) antibody responses against 2018/2019 QIV strains from baseline (Day 1) to approximately Day 29 after receipt of 2018/2019 Fluzone and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 3) to assess the serum neuraminidase inhibition antibody (NAI) responses by enzyme-linked lectin assay (ELLA) against NA antigens in the 2018/2019 QIV from baseline (Day 1) to approximately Day 29 after receipt of 2018/2019 Fluzone and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 4) to assess the influenza neutralizing (Neut) antibody titer responses against 2018/2019 QIV strains from baseline (Day 1) to approximately Day 29 after receipt of 2018/2019 Fluzone and Flublok with and without AF03 or Advax- CpG55.2 adjuvant.

  • Condition or Disease:Influenza
    Influenza Immunisation
  • Intervention/Treatment: Drug: AF03
    Biological: Delta Inulin-CpG55.2
    Biological: Influenza Virus Quadrivalent Inactivated Vaccine
    Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine
  • Phase: Phase 1
Detailed Description

This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of either the 2018/2019 seasonal Fluzone or Flublok Quadrivalent Influenza Vaccine (QIV) manufactured by Sanofi Pasteur (SP) given without adjuvant or with one of two adjuvant formulations, AF03 or Advax-CpG55.2. Subjects will be stratified by prior receipt of licensed, seasonal influenza vaccine (defined as receipt of at least one of the 2017/2018 and/or 2018/2019 influenza vaccines) and will be randomly assigned to 1 of 6 treatment arms to receive a single dose of one of the two seasonal 2018/2019 QIV vaccine formulations with or without one of the two adjuvants (Day 1). On approximately Day 90, each subject will receive a single dose of the seasonal 2019/2020 QIV. Groups 1, 2 and 3 will receive 2019/2020 Fluzone QIV and Groups 4, 5 and 6 will receive 2019/2020 Flublok QIV. Eight Vaccine and Treatment Evaluation Unit (VTEU) sites will be included in the study. Study duration is approximately 18 months, and subject participation duration is 12 months. The primary objectives of this study are: 1) to assess the safety and reactogenicity of 2018/2019 Fluzone and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 2) to assess the serum hemagglutination inhibition (HAI) antibody responses against 2018/2019 QIV strains from baseline (Day 1) to approximately Day 29 after receipt of 2018/2019 Fluzone and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 3) to assess the serum neuraminidase inhibition antibody (NAI) responses by enzyme-linked lectin assay (ELLA) against NA antigens in the 2018/2019 QIV from baseline (Day 1) to approximately Day 29 after receipt of 2018/2019 Fluzone and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 4) to assess the influenza neutralizing (Neut) antibody titer responses against 2018/2019 QIV strains from baseline (Day 1) to approximately Day 29 after receipt of 2018/2019 Fluzone and Flublok with and without AF03 or Advax- CpG55.2 adjuvant. The secondary objectives of this study are: 1) to assess protocol specified adverse events of special interest (AESI), medically-attended adverse events (MAAEs), including new-onset chronic medical conditions (NOCMCs) and potentially immune-mediated medical conditions (PIMMCs) that occur after receipt of study product; 2) to assess the HAI, Neut and NAI ELLA responses to the 2019/2020 QIV strains prior to (Day 1) and approximately 28 days after vaccination with the 2019/2020 QIV in all study groups; 3) to assess the HAI antibody responses against heterologous influenza A/H1 and H3 strains from baseline (Day 1) to approximately Days 8, 29, 57, 90 and 118 after receipt of 2018/2019 Fluzone or Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 4) to assess NAI ELLA responses against heterologous N1 and N2 NA antigens from baseline (Day 1) to approximately Days 8, 29, 57, 90 and 118 after administration of 2018/2019 Fluzone with and without AF03 or Advax-CpG55.2 adjuvant; 5) to assess the influenza neutralizing (Neut) antibody titer responses against heterologous influenza A/H1 and H3 strains from baseline (Day 1) to approximately Days 8, 29, 57, 90 and 118 after administration of 2018/2019 Fluzone and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 6) to assess the longitudinal kinetics and durability of the HAI, NAI, and Neut responses against the 2018/2019 QIV strains on approximately Days 8, 57, 90 and 118 following receipt of the 2018/2019 Fluzone and Flublok with and without AF03 or Advax-CpG55.2 adjuvant.

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 241 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Prevention
  • Official Title: A Phase I Study to Assess the Safety, Reactogenicity and Immunogenicity of Two Quadrivalent Seasonal Influenza Vaccines (Fluzone(R) or Flublok(R)) With or Without One of Two Adjuvants (AF03 or Advax-CpG55.2) in Healthy Adults 18-45 Years of Age
  • Actual Study Start Date: June 2019
  • Actual Primary Completion Date: September 2020
  • Actual Study Completion Date: September 2020
Arms and interventions
Arm Intervention/treatment
Experimental: Group 2
0.5 mL of 2018/2019 Fluzone QIV + 0.25 mL of AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
Drug: AF03
A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether

Biological: Influenza Virus Quadrivalent Inactivated Vaccine
2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
Experimental: Group 5
0.5 mL of 2018/2019 Flublok QIV + 0.25 mL AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
Drug: AF03
A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether

Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine
2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
Experimental: Group 3
0.5 mL of 2018/2019 Fluzone QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 2019/2020 of Fluzone QIV intramuscular injection on Day 90, n=40
Biological: Delta Inulin-CpG55.2
A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)

Biological: Influenza Virus Quadrivalent Inactivated Vaccine
2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
Experimental: Group 6
0.5 mL of 2018/2019 Flublok QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
Biological: Delta Inulin-CpG55.2
A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)

Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine
2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
Experimental: Group 1
0.5 mL of 2018/2019 Fluzone QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
Biological: Influenza Virus Quadrivalent Inactivated Vaccine
2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
Experimental: Group 4
0.5 mL of 2018/2019 Flublok QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine
2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
Outcome Measures
  • Primary Outcome Measures: 1. Geometric mean fold rise (GMFR) in hemagglutination inhibition (HAI) titers against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 29 ]
  • 2. Geometric mean fold rise (GMFR) in neuraminidase inhibition (NAI) titers against neuraminidase (NA) antigens in the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 29 ]
  • 3. Geometric mean fold rise (GMFR) in neutralizing (Neut) titers against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 1 through Day 29 ]
  • 4. Geometric mean titers (GMTs) of serum hemagglutination inhibition (HAI) against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strain [ Time Frame: Day 1 through Day 29 ]
  • 5. Occurrence of abnormal clinical safety laboratory adverse events (AEs) [ Time Frame: Day 1 through Day 8 ]
  • 6. Occurrence of all serious adverse events (SAEs) [ Time Frame: Day 1 through Day 365 ]
  • 7. Occurrence of solicited reactogenicity events [ Time Frame: Day 1 through Day 8 ]
    Both local and systemic AEs will be assessed
  • 8. Occurrence of unsolicited adverse events (AEs) [ Time Frame: Day 1 through Day 29 ]
  • 9. Percentage of subjects achieving hemagglutination inhibition (HAI) titer seroconversion against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 29 ]
    HAI seroconversion defined as either a pre-vaccination titer < 1:10 and a post-vaccination titer >/= 1:40 or a pre-vaccination titer >/= 1:10 and a minimum four-fold rise in post-vaccination antibody titer.
  • 10. Percentage of subjects achieving neuraminidase inhibition (NAI) seroconversion [ Time Frame: Day 29 ]
    NAI seroconversion defined as >/= 4-fold rise in post vaccination antibody titers against the NA antigens in the 2018/2019 QIV.
  • 11. Percentage of subjects achieving neutralizing (Neut) titer seroconversion against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 29 ]
    Neut titer seroconversion defined as either a pre-vaccination titer < 1:10 and a post-vaccination titer >/= 1:40 or a pre-vaccination titer >/= 1:10 and a minimum four-fold rise in post-vaccination antibody titer.
  • 12. Percentage of subjects with a neutralizing (Neut) titer >/= 1:40 against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 1 through Day 29 ]
  • 13. Percentage of subjects with hemagglutination inhibition (HAI) titer >/= 1:40 against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 1 through Day 29 ]
  • 14. Ratio of geometric mean titers (GMTs) of serum hemagglutination inhibition (HAI) against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups [ Time Frame: Day 1 through Day 29 ]
  • 15. Ratio of serum neuraminidase inhibition (NAI) geometric mean titer (GMT) between adjuvanted and unadjuvanted study groups [ Time Frame: Day 1 through Day 29 ]
  • 16. Ratio of serum neutralizing (Neut) geometric mean titer (GMT) between adjuvanted and unadjuvanted study groups [ Time Frame: Day 1 through Day 29 ]
  • 17. Serum neuraminidase inhibition (NAI) geometric mean titer (GMT) [ Time Frame: Day 1 through Day 29 ]
  • 18. Serum neutralizing (Neut) geometric mean titer (GMT) [ Time Frame: Day 1 through Day 29 ]
  • Secondary Outcome Measures: 1. Geometric mean fold rise (GMFR) in hemagglutination inhibition (HAI) against heterologous H1 and H3 influenza strains [ Time Frame: Day 1 through Day 118 ]
  • 2. Geometric mean fold rise (GMFR) in hemagglutination inhibition (HAI) titers against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 1 through Day 118 ]
  • 3. Geometric mean fold rise (GMFR) in neuraminidase inhibition (NAI) titers against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 1 through Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 4. Geometric mean fold rise (GMFR) in neutralizing (Neut) titers against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 1 through Day 118 ]
  • 5. Geometric mean fold rise (GMFR) in serum neuraminidase inhibition (NAI) against heterologous N1 and N2 neuraminidase (NA) antigens [ Time Frame: Day 1 through Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 6. Geometric mean fold rise (GMFR) of neutralizing (Neut) antibody titers against heterologous H1 and H3 influenza strains [ Time Frame: Day 1 through Day 118 ]
  • 7. Occurrence of protocol specified adverse events of special interests (AESIs) [ Time Frame: Day 1 through Day 365 ]
  • 8. Occurrence of protocol specified medically-attended adverse events (MAAEs [ Time Frame: Day 1 through Day 365 ]
    Including new-onset chronic medical conditions (NOCMCs) and potentially immune-mediated medical conditions (PIMMCs)
  • 9. Percentage of subjects achieving a hemagglutination inhibition (HAI) titer >/= 1:40 against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 8 through Day 118 ]
  • 10. Percentage of subjects achieving a hemagglutination inhibition (HAI) titer >/= 1:40 against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 90 through Day 118 ]
  • 11. Percentage of subjects achieving a hemagglutination inhibition (HAI) titer >/= 1:40 against heterologous H1 and H3 influenza strains [ Time Frame: Day 1 through Day 118 ]
  • 12. Percentage of subjects achieving hemagglutination inhibition (HAI) titer seroconversion against 2018/2019 Quadrivalent Influenza Vaccine (QIV) antigens and strains [ Time Frame: Day 8 through Day 118 ]
  • 13. Percentage of subjects achieving hemagglutination inhibition (HAI) titer seroconversion against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 118 ]
  • 14. Percentage of subjects achieving hemagglutination inhibition (HAI) titer seroconversion against heterologous H1 and H3 influenza strains [ Time Frame: Day 8 through Day 118 ]
  • 15. Percentage of subjects achieving neuraminidase inhibition (NAI) titer seroconversion against 2018/2019 Quadrivalent Influenza Vaccine (QIV) antigens and strains [ Time Frame: Day 8 through Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 16. Percentage of subjects achieving neuraminidase inhibition (NAI) titer seroconversion against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 17. Percentage of subjects achieving neutralizing (Neut) titer >/= 1:40 against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 8 through Day 118 ]
  • 18. Percentage of subjects achieving neutralizing (Neut) titer seroconversion against 2018/2019 Quadrivalent Influenza Vaccine (QIV) antigens and strains [ Time Frame: Day 8 through Day 118 ]
  • 19. Percentage of subjects achieving neutralizing (Neut) titer seroconversion against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 118 ]
  • 20. Percentage of subjects achieving neutralizing (Neut) titer seroconversion against heterologous H1 and H3 influenza strains [ Time Frame: Day 8 through Day 118 ]
  • 21. Percentage of subjects achieving seroconversion against heterologous N1 and N2 neuraminidase (NA) antigens [ Time Frame: Day 8 through Day 118 ]
    NA antigens will only be assessed on study groups 1, 2, and 3.
  • 22. Ratio of serum hemagglutination inhibition (HAI) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups [ Time Frame: Day 8 through Day 118 ]
  • 23. Ratio of serum hemagglutination inhibition (HAI) geometric mean titer (GMT) against heterologous H1 and H3 influenza strains between adjuvanted and unadjuvanted study groups [ Time Frame: Day 1 through Day 118 ]
  • 24. Ratio of serum hemagglutination inhibition (HAI) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups [ Time Frame: Day 90 through Day 118 ]
  • 25. Ratio of serum neuraminidase inhibition (NAI) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups [ Time Frame: Day 8 through Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 26. Ratio of serum neuraminidase inhibition (NAI) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups [ Time Frame: Day 90 through Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 27. Ratio of serum neuraminidase inhibition (NAI) geometric mean titers (GMTs) against heterologous N1 and N2 neuraminidase (NA) antigens between adjuvanted and unadjuvanted study groups [ Time Frame: Day 1 through Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 28. Ratio of serum neutralizing (Neut) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups [ Time Frame: Day 8 through Day 118 ]
  • 29. Ratio of serum neutralizing (Neut) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups [ Time Frame: Day 90 through Day 118 ]
  • 30. Ratio of serum neutralizing (Neut) geometric mean titers (GMTs) against heterologous H1 and H3 influenza strains between adjuvanted and unadjuvanted study groups [ Time Frame: Day 1 through Day 118 ]
  • 31. Serum hemagglutination inhibition (HAI) geometric mean fold rise (GMFR) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 90 through Day 118 ]
  • 32. Serum hemagglutination inhibition (HAI) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 8 through Day 118 ]
  • 33. Serum hemagglutination inhibition (HAI) geometric mean titer (GMT) against heterologous H1 and H3 influenza strains [ Time Frame: Day 1 through Day 118 ]
  • 34. Serum hemagglutination inhibition (HAI) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 90 through Day 118 ]
  • 35. Serum neuraminidase inhibition (NAI) geometric mean fold rise (GMFR) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 90 through Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 36. Serum neuraminidase inhibition (NAI) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 8 through Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 37. Serum neuraminidase inhibition (NAI) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 90 through Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 38. Serum neuraminidase inhibition (NAI) geometric mean titers (GMTs) against heterologous N1 and N2 neuraminidase (NA) antigens [ Time Frame: Day 1 through Day 118 ]
    NAI titers will only be assessed on study groups 1, 2, and 3.
  • 39. Serum neutralizing (Neut) geometric mean fold rise (GMFR) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 90 through Day 118 ]
  • 40. Serum neutralizing (Neut) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 8 through Day 118 ]
  • 41. Serum neutralizing (Neut) geometric mean titer (GMT) against heterologous H1 and H3 influenza strains [ Time Frame: Day 1 through 118 ]
  • 42. Serum neutralizing (Neut) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains [ Time Frame: Day 90 through Day 118 ]
Eligibility Criteria
  • Ages Eligible for Study: 18 to 45 Years (Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

1. Provide written informed consent prior to initiation of any study procedures.

2. Are able to understand and comply with planned study procedures and be available for
all study visits.

3. Must agree to the collection of venous blood per protocol.

4. Are males or non-pregnant females, 18 to 45 years of age, inclusive at time of
enrollment.

5. Are in good health*. *As determined by medical history and physical examination to
evaluate acute or currently ongoing chronic medical or psychiatric diagnoses or
conditions, defined as those that have been present for at least 90 days, which would
affect the assessment of the safety of subjects or the immunogenicity of study
vaccinations. Chronic medical diagnoses or conditions should be stable for the last 60
days (no hospitalizations, emergency room or urgent care for condition, or invasive
medical procedure and no adverse symptoms that need medical intervention such as
medication change/supplemental oxygen). This includes no change in chronic
prescription medication, dose or in the 60 days prior to enrollment. Any prescription
change that is due to change of health care provider, insurance company, etc., or that
is done for financial reasons, as long as in the same class of medication, will not be
considered a deviation of this inclusion criterion. Subjects may be on chronic or as
needed (prn) medications if, in the opinion of the site PI or appropriate
sub-investigator, they pose no additional risk to subject safety or assessment of
reactogenicity and immunogenicity and do not indicate a worsening or treatment of
continued symptoms of medical diagnosis or condition. Note: Low dose topical,
corticosteroids as outlined in the Subject Exclusion Criteria as well as herbals,
vitamins and supplements are permitted.

6. Oral temperature is less than 100.0 degrees Fahrenheit.

7. Pulse is 47 to 100 beats per minute, inclusive.

8. Systolic blood pressure is 85 to 140 mmHg, inclusive.

9. Diastolic blood pressure is 55 to 90 mmHg, inclusive.

10. Screening laboratories (Erythrocyte Sedimentation Rate (ESR), White Blood Cells (WBC),
Hemoglobin (Hgb), Platelets (PLTs), Alanine Aminotransferase (ALT), Total Bilirubin
(T. Bili), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT),
Alkaline Phosphatase (ALP) serum lipase, serum amylase and Creatinine (Cr)) are within
acceptable parameters*.

*ESR must be below 30 mm/hr; WBC >3.90 K/MM3 and /= 11.5 g/dl
(women) or >/= 12.5 g/dl (men); PLTs (EDTA) 140-415 K/MM3; PLTs (Citrate) 125-325
K/MM3 ALT </= 43 U/L (women) or </= 60 U/L (men); T Bili </=1.20 mg/dl; Cr < 1.1 mg/dl (women) or < 1.4 mg/dl (men); AST 10-36 U/L (women) or 10-43 U/L (men); GGT 5--32 U/L (women) or 10-49 U/L (men); ALP 30-115 U/L (women) or 43-115 U/L (men); lipase 13-60 U/L; amylase (Total) 35-121 U/L, for subjects to qualify for randomization and vaccination. 11. Women of childbearing potential* must use an acceptable contraception method** from at least 30 days before the first study vaccination until 60 days after the second study vaccination. *Not sterilized via bilateral oophorectomy, tubal ligation/ salpingectomy, hysterectomy, or successful Essure(R) placement (permanent, non-surgical, non-hormonal sterilization) with documented radiological confirmation test at least 90 days after the procedure, and still menstruating or <1 year has passed since the last menses if menopausal. - Includes non-male sexual relationships, full abstinence from sexual intercourse with a male partner, monogamous relationship with vasectomized partner who has been vasectomized for 180 days or more and shown to be azoospermic prior to the subject receiving the study vaccination, barrier methods such as condoms or diaphragms/cervical cap with spermicide, effective intrauterine devices, NuvaRing(R), and licensed hormonal methods such as implants, injectables or oral contraceptives ("the pill"). 12. Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to the first study vaccination. 13. For a woman with potential to become pregnant, she understands that in the event of pregnancy during the study she will be approached to enroll in the Sanofi Pregnancy Registry. 14. Must agree to have residual specimens (i.e. residual/excess of per protocol specifications). Exclusion Criteria: 1. Have an acute illness*, as determined by the site Principal Investigator (PI) or appropriate sub-investigator, within 72 hours prior to study vaccination. *An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the site PI or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol. 2. Have any medical disease or condition that, in the opinion of the site PI or appropriate sub-investigator, is a contraindication to study participation*. *Including acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial. 3. Have immunosuppression as a result of an underlying illness or treatment, a recent history or current use of immunosuppressive or immunomodulating disease therapy. 4. Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior to study vaccination. 5. Have known active or recently active (12 months) neoplastic disease or a history of any hematologic malignancy. Non-melanoma, treated, skin cancers are permitted. 6. Have known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection. 7. Have known hypersensitivity or allergy to eggs, egg or chicken protein, squalene-based adjuvants, or other components of the study vaccine. 8. Have a history of severe reactions following previous immunization with licensed or unlicensed influenza vaccines. 9. Have a history of Guillain-Barré Syndrome (GBS). 10. Have a history of convulsions or encephalomyelitis within 90 days prior to study vaccination. 11. Have a history of Potentially Immune-Mediated Medical Conditions (PIMMCs). 12. Have a history of alcohol or drug abuse within 5 years prior to study vaccination. 13. Have any diagnosis, current or past, of schizophrenia, bipolar disease or other psychiatric diagnosis that may interfere* with subject compliance or safety evaluations. *As determined by the site PI or appropriate sub-investigator. 14. Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others within 5 years prior to study vaccination. 15. Have taken oral or parenteral (including intra-articular) corticosteroids of any dose within 30 days prior to study vaccination. 16. Have taken high-dose inhaled corticosteroids* within 30 days prior to study vaccination. *High-dose defined as per age as using inhaled high-dose per reference chart in the National Heart, Lung and Blood Institute Guidelines for the Diagnosis and Management of Asthma (EPR-3) or other lists published in UPTODATE. 17. Received or plan to receive a licensed, live vaccine (excluding all licensed, seasonal LAIVs) within 30 days before or after the study vaccination. 18. Received or plan to receive a licensed, inactivated vaccine (excluding all licensed, seasonal IIVs) within 14 days before or after each study vaccination. 19. Have received any 2018/2019 seasonal influenza vaccine within the 6 months prior to enrollment. 20. Plans to receive any 2019/2020 seasonal influenza vaccine within approximately 90 days of receipt of the first study vaccination. 21. Have a known history of documented influenza infection within the past 6 months. 22. Received immunoglobulin or other blood products (except Rho D immunoglobulin) within 90 days prior to study vaccination. 23. Received an experimental agent* within 30 days prior to the study vaccination or expect to receive another experimental agent* during the trial-reporting period*. *Including vaccine, drug, biologic, device, blood product, or medication. **Other than from participation in this trial. ***Approximately 12 months after the first study vaccination. 24. Are participating or plan to participate in another clinical trial with an interventional agent* that will be received during the trial-reporting period**. *Including licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication. **Approximately 12 months after the first study vaccination. 25. Female subjects who are breastfeeding or plan to breastfeed from the time of the first study vaccination through 30 days after the last study vaccination. 26. Plan to travel outside the US (continental US, Hawaii and Alaska) from the time of study vaccination through approximately 90 days after the first study vaccination. 27. Planning to donate blood within 4 months following first vaccination. Exclusion Criteria for Second Study Vaccination: All study participants will be expected to receive the second study vaccination except under the circumstances listed below. The second study vaccination will not be administered to a subject if any of the following criteria are met: - Meets the contraindication on the package insert to receipt of licensed influenza vaccine. - As deemed necessary by the site principal investigator or appropriate sub-investigator for noncompliance or other reasons. - Subject refusal of further study vaccination. - Withdrawal of consent. - Subject is lost to follow-up. - Termination of this trial. - New information becomes available that makes further participation unsafe.

Contacts and Locations
Contacts
Locations

United States, Georgia
Emory Children's Center - Pediatric Infectious Diseases
Atlanta

United States, Iowa
University of Iowa - Vaccine Research and Education Unit
Iowa City

United States, Maryland
University of Maryland Baltimore - School of Medicine - Medicine
Baltimore

United States, Missouri
Saint Louis University - Center for Vaccine Development
Saint Louis

United States, North Carolina
Duke Human Vaccine Institute - Duke Vaccine and Trials Unit
Durham

United States, Ohio
Cincinnati Children's Hospital Medical Center - Infectious Diseases
Cincinnati

United States, Tennessee
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center
Nashville

United States, Texas
Baylor College of Medicine - Molecular Virology and Microbiology
Houston

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

More Information
  • Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
  • ClinicalTrials.gov Identifier: NCT03945825 History of Changes
  • Other Study ID Numbers: 18-0011, HHSN272201300015I
  • First Posted: May 10, 2019 Key Record Dates
  • Last Update Posted: March 2, 2021
  • Last Verified: February 2021
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID): Immunogenicity
    Influenza Vaccine
    Phase 1
    Quadrivalent
    Safety
    Influenza
  • Additional relevant MeSH terms: Influenza, Human